Ingo Jordan

This inventor holds 8 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignees: Probiogen Ag, Probiogen Ab. Active years: 2014-2021.

USPTO Granted Patents = 8 (Patent Applications = 3)

% Patents Active = 87.5

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 14)

Average Co-Inventor Count = 2.7

ph-index = 1

Forward Citations = 7(Granted Patents)

Company Filing History:

Years Active: 2014-2021

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11104884 - Vaccinia virus vectors related to MVA with extensive genomic symmetries (2021-08-31),

2. 11060069 - Porcine cell line for virus production (2021-07-13),

3. 9765158 - Methods for preparation of fucose-linked site specific conjugates of proteins with toxins, adjuvants, detection labels and pharmacokinetic half life extenders (2017-09-19),

4. 9732325 - MVA virus and uses thereof (2017-08-15),

5. 9273289 - Depletion of host cell components from live vector vaccines (2016-03-01),

6. 8940534 - Immortalized avian cell lines for virus production (2015-01-27),

7. 8815540 - Productivity augmenting protein factor, novel cell lines and uses thereof (2014-08-26),

8. 8679839 - Cell line from rousettus as host cell for pathogen amplification (2014-03-25),

Title: Ingo Jordan: Innovator in Viral Vector Technology

Introduction

Ingo Jordan is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of viral vector technology, holding a total of 8 patents. His work focuses on the development of innovative methods and compositions related to Modified Vaccinia Ankara (MVA) and other viral applications.

Latest Patents

One of Ingo Jordan's latest patents involves the use of vaccinia virus vectors related to MVA with extensive genomic symmetries. This invention pertains to a novel MVA-related virus, along with methods for culturing and producing this virus. Additionally, it includes a pharmaceutical composition that comprises the MVA-related virus and various pharmaceutical acceptable excipients, diluents, and carriers. Furthermore, the invention outlines a vaccine that incorporates the MVA-related virus for medical use.

Another significant patent by Ingo Jordan is centered around a continuous porcine cell line designed for virus production. This cell line can proliferate in a medium free of animal-derived components. The invention also details methods for producing a virus using this cell line, as well as a method for accumulating a virus from environmental samples.

Career Highlights

Ingo Jordan has worked with notable companies in the biotechnology sector, including Probiogen AG and Probiogen AB. His experience in these organizations has allowed him to advance his research and contribute to the development of cutting-edge viral technologies.

Collaborations

Ingo Jordan has collaborated with esteemed colleagues in his field, including Volker Sandig and Deborah Horn. These partnerships have further enriched his research and innovation efforts.

Conclusion

Ingo Jordan's work in viral vector technology exemplifies his commitment to advancing medical science through innovative inventions. His contributions continue to impact the field significantly, paving the way for future developments in vaccine and virus production technologies.